A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alnylam Pharmaceuticals
- ID
- NCT03841448
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated